Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ARGX

Argen X SE ADR

Dec 13 • 04:00PM ET

607.21

Dollar change +3.80
Percentage change 0.63	%

Healthcare • Biotechnology • Netherlands • NASD

Peers: REGN VRTX BIIB INCY IONS GILD NBIX RCUS FGEN XBIT

| Held by: IBB FBT CGGO BBH QQQJ ONEQ FDG TCAF DFAI AVDE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.50	Insider Own	1.35%	Shs Outstand	60.37M	Perf Week	-2.55%
Market Cap	36.66B	Forward P/E	64.62	EPS next Y	9.40	Insider Trans	0.00%	Shs Float	59.55M	Perf Month	1.31%
Income	-204.55M	PEG	-	EPS next Q	1.26	Inst Own	57.18%	Short Float	3.29%	Perf Quarter	12.88%
Sales	1.61B	P/S	22.70	EPS this Y	140.47%	Inst Trans	-0.94%	Short Ratio	7.49	Perf Half Y	56.90%
Book/sh	71.28	P/B	8.52	EPS next Y	349.98%	ROA	-5.12%	Short Interest	1.96M	Perf Year	31.58%
Cash/sh	51.39	P/C	11.82	EPS next 5Y	-	ROE	-5.75%	52W Range	327.73 - 630.00	Perf YTD	59.61%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-17.05%	ROI	-4.77%	52W High	-3.62%	Beta	0.59
Dividend TTM	-	Quick Ratio	7.88	Sales past 5Y	287.78%	Gross Margin	82.74%	52W Low	85.28%	ATR (14)	12.22
Dividend Ex-Date	-	Current Ratio	8.53	EPS Y/Y TTM	51.16%	Oper. Margin	-24.56%	RSI (14)	54.48	Volatility	1.61% 1.92%
Employees	1148	Debt/Eq	0.01	Sales Y/Y TTM	101.07%	Profit Margin	-12.67%	Recom	1.30	Target Price	668.65
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	10.02%	Payout	-	Rel Volume	0.75	Prev Close	603.40
Sales Surprise	9.34%	EPS Surprise	847.51%	Sales Q/Q	82.26%	Earnings	Oct 31 BMO	Avg Volume	261.15K	Price	607.21
SMA20	0.53%	SMA50	4.82%	SMA200	28.14%	Trades		Volume	195,325	Change	0.63%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-12-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$697
Nov-05-24	Upgrade	Scotiabank	Sector Perform → Sector Outperform	$715
Nov-01-24	Upgrade	William Blair	Mkt Perform → Outperform
Nov-01-24	Downgrade	Robert W. Baird	Outperform → Neutral	$515 → $650
Oct-10-24	Resumed	Raymond James	Strong Buy	$605
Oct-04-24	Downgrade	Deutsche Bank	Buy → Hold
Aug-06-24	Upgrade	Barclays	Equal Weight → Overweight
Jul-25-24	Upgrade	Deutsche Bank	Hold → Buy
Jul-23-24	Upgrade	Oppenheimer	Perform → Outperform	$546
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-20-23	Downgrade	William Blair	Outperform → Mkt Perform
Dec-20-23	Downgrade	Deutsche Bank	Buy → Hold
Jul-31-23	Initiated	Scotiabank	Sector Perform	$516
Jul-24-23	Downgrade	UBS	Buy → Neutral	$480 → $570
Jul-17-23	Resumed	Evercore ISI	Outperform	$436
Jun-15-23	Initiated	Societe Generale	Sell
May-31-23	Initiated	UBS	Buy	$480
Apr-25-23	Initiated	Citigroup	Buy	$450
Mar-14-23	Upgrade	Robert W. Baird	Neutral → Outperform	$460
Dec-07-22	Initiated	William Blair	Outperform

Show Previous Ratings

Dec-12-24 09:30AM	Heres Why argenx SE (ARGX) Surged in Q3 (Insider Monkey)
Dec-09-24 09:10AM	Should You Increase Your Holdings in argenx SE (ARGX)? (Insider Monkey)
Dec-02-24 02:55PM	Why Is Argenx SE (ARGX) Among the Best High Growth Healthcare Stocks to Invest In Now? (Insider Monkey)
Nov-26-24 01:00AM	argenx to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-22-24 05:30AM	Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial (BioPharma Dive)
01:00AM	Loading…
Nov-20-24 01:00AM	argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies (GlobeNewswire)
Nov-18-24 09:10AM	Is argenx SE (ARGX) the Best Immunotherapy Stock to Buy Now? (Insider Monkey)
Nov-11-24 07:30AM	Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China (Business Wire)
07:30AM	argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China (GlobeNewswire)
Nov-05-24 12:20PM	Why Argenx (ARGX) Might be Well Poised for a Surge (Zacks)
01:00AM	argenx to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-02-24 10:40AM	Argenx price target raised to $660 from $540 at Truist (TipRanks)
Nov-01-24 03:06AM	argenx SE (ARGNF) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Challenges (GuruFocus.com)
Oct-31-24 03:39PM	Analyst Report: argenx SE (Morningstar Research) +6.27%
03:00PM	Here's Why You Should Hold Argenx SE (ARGX) (Insider Monkey)
02:00AM	Loading…
02:00AM	argenx Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-24-24 01:00AM	argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024 (GlobeNewswire)
Oct-16-24 10:29AM	Multiple Tailwinds Lifted argenx SE (ARGX) in Q3 (Insider Monkey)
Oct-15-24 01:00AM	argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions (GlobeNewswire)
Oct-09-24 03:14PM	argenx SE (ARGNF) Q2 2024 Earnings Call Highlights: Strong Financial Performance Amid ... (GuruFocus.com)
Oct-02-24 09:43AM	Biotech Leader Argenx In Buy Zone, Poised To Hit New Highs (Investor's Business Daily)
Sep-25-24 04:15PM	Amgen stock falls on lackluster drug data (Yahoo Finance Video) +5.63%
04:05PM	Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases (Investor's Business Daily)
Sep-19-24 01:00AM	argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy (GlobeNewswire)
Sep-12-24 10:09PM	Here's Why argenx SE (ARGX) Rose 9% in Q2 (Insider Monkey)
Sep-06-24 01:31PM	Four Biotech Stocks Rally Toward Buy Points As Funds Load Up (Investor's Business Daily)
08:39AM	Argenx (ARGX) Moves 4.0% Higher: Will This Strength Last? (Zacks)
Aug-29-24 12:29PM	Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB (Benzinga)
Aug-28-24 01:00AM	argenx to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-12-24 03:59PM	Biotech stocks: Which drugmakers are worth a buy? (Yahoo Finance Video)
12:00PM	Loading…
Jul-30-24 12:00PM	Argenx (ARGX) Upgraded to Buy: Here's What You Should Know (Zacks)
Jul-25-24 08:30PM	Analyst Report: argenx SE (Morningstar Research)
01:00AM	argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update (GlobeNewswire)
Jul-18-24 01:00AM	argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024 (GlobeNewswire)
Jul-16-24 07:04AM	What Made argenx SE (ARGX) Rise in Q2? (Insider Monkey)
12:30AM	argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China (GlobeNewswire)
12:15AM	Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China (Business Wire)
Jun-25-24 04:30PM	argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting (GlobeNewswire)
04:06AM	Argenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains? (Zacks)
Jun-24-24 04:11PM	Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval (Investor's Business Daily) +11.69%
10:19AM	FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder (Zacks)
06:53AM	FDA approves argenxs VYVGART Hytrulo for CIDP treatment (Pharmaceutical Technology)
05:15AM	Argenx soars on CIDP shot approval (Investing.com)
Jun-21-24 04:50PM	argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (GlobeNewswire)
Jun-17-24 01:00AM	argenx to unveil its 'Vision 2030: Taking Breakthrough Science to 50,000 Patients' during its Upcoming R&D Day on July 16, 2024 (GlobeNewswire)
Jun-06-24 06:37PM	Analyst Report: argenx SE (Morningstar Research)
Jun-04-24 01:00AM	argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-30-24 04:02PM	After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay (Investor's Business Daily)
May-29-24 04:06PM	Biohaven Tumbles After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump (Investor's Business Daily)
10:17AM	Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump (Investor's Business Daily)
May-14-24 06:43PM	Analyst Report: argenx SE (Morningstar Research) +5.88%
May-13-24 10:30AM	JPMorgan Cuts Price Target on Argenx to $500 From $560, Maintains Overweight Rating (MT Newswires)
May-10-24 04:25PM	argenx SE (NASDAQ:ARGX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 12:28PM	Analyst Report: argenx SE (Morningstar Research)
06:52AM	ARGX Stock Earnings: argenx Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
01:00AM	argenx Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-08-24 10:56AM	Is a Surprise Coming for argenx (ARGX) This Earnings Season? (Zacks)
May-07-24 05:30PM	argenx announces results of Annual General Meeting of Shareholders (GlobeNewswire)
01:00AM	argenx to Present at BofA Securities 2024 Health Care Conference (GlobeNewswire)
May-02-24 06:42PM	Analyst Report: argenx SE (Morningstar Research)
01:00AM	argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024 (GlobeNewswire)
Apr-16-24 01:00AM	argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease (GlobeNewswire)
Mar-29-24 04:42AM	Here's Why argenx SE (ARGX) Pulled Back 23% in Q4 (Insider Monkey)
Mar-27-24 02:00AM	argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease (GlobeNewswire)
Mar-26-24 04:00PM	argenx Announces Annual General Meeting of Shareholders on May 7, 2024 (GlobeNewswire)
02:00AM	argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia (GlobeNewswire)
Mar-22-24 10:28AM	Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday (Zacks)
07:47AM	Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last? (Zacks)
Mar-21-24 04:45PM	Argenx, Immunovant Soar As Tourmaline Plummets On A Rival's Lackluster Test Results (Investor's Business Daily) +11.19%
Mar-20-24 06:38PM	Analyst Report: argenx SE (Morningstar Research)
Mar-19-24 07:16AM	Reasons to Invest in argenx (ARGX) (Insider Monkey)
Mar-17-24 08:49AM	5 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-07-24 04:01PM	argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting (GlobeNewswire)
08:14AM	Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4 (Insider Monkey)
07:28AM	Should You be Confident in Your Investment in argenx SE (ARGX)? (Insider Monkey)
Mar-01-24 10:12AM	argenx SE (NASDAQ:ARGX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 10:16PM	Analyst Report: argenx SE (Morningstar Research)
01:00AM	argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update (GlobeNewswire)
Feb-28-24 08:38AM	Is a Surprise Coming for argenx (ARGX) This Earnings Season? (Zacks)
Feb-26-24 01:00AM	argenx to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-22-24 08:00AM	Argenx Is Tracking Well Above the Industry (GuruFocus.com)
01:00AM	argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024 (GlobeNewswire)
Feb-21-24 10:08PM	3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition (InvestorPlace)
Feb-20-24 01:00AM	argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy (GlobeNewswire)
Jan-22-24 05:35AM	Argenx SE (ARGX) Declined on Failed Clinical Trials (Insider Monkey)
Jan-18-24 01:00AM	argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis (GlobeNewswire)
Jan-12-24 08:30AM	How Argenx (ARGX) Stock Stands Out in a Strong Industry (Zacks)
Jan-08-24 01:00AM	argenx Highlights 2024 Strategic Priorities (GlobeNewswire)
Jan-04-24 06:44PM	Analyst Report: argenx SE (Morningstar Research)
Jan-02-24 01:00AM	argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-22-23 05:05AM	UPDATE 2-European shares end slightly higher ahead of Christmas holiday (Reuters) +5.30%
Dec-21-23 04:09PM	Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off (Investor's Business Daily)
09:50AM	argenx (ARGX) Tanks on Top-Line Data From Pemphigus Study (Zacks)
Dec-20-23 04:33PM	Stock Market Does Sharp About-Face; Dow Breaks Win Streak (Investor's Business Daily) -25.12%
04:02PM	Argenx Crashes 25% As The Setbacks Mount For Its Hallmark Drug, Vyvgart (Investor's Business Daily)
03:20PM	Stock Market Reverses Sharply Lower; FedEx Stock Worst In S&P 500 (Investor's Business Daily)
12:15PM	Analyst Report: argenx SE (Morningstar Research)
07:26AM	Argenx Dives On Autoimmune Therapy Failure (Investor's Business Daily)
06:30AM	Argenx autoimmune drug study fails in blow to expansion hopes (BioPharma Dive)
01:00AM	argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus (GlobeNewswire)

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARGX

Argen X SE ADR

Upgrade your FINVIZ experience